Biomarkers like HER2, PD-L1, and Ki-67, which have been associated with tumor aggressiveness and chemoresistance in other malignancies, may also serve as indicators of relapse risk and long-term prognosis in GTN. This evidence concerns the gene ERBB2 and gestational trophoblastic neoplasm.